文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

度洛西汀预给药预防带状疱疹后神经痛:PROCESS随机对照试验方案

Effect of duloxetine premedication for postherpetic neuralgia within 72 h of herpes zoster reactivation [PROCESS]: a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-12-09

本研究为全国多中心、随机、开放标签、盲法终点的试验方案,计划在中国18个中心招募750例50岁以上、带状疱疹皮疹出现72小时内且VAS平均疼痛评分至少40/100 mm的患者。受试者随机分为度洛西汀组(抗病毒药+镇痛药+度洛西汀)和对照组(抗病毒药+镇痛药),主要结局为12周时VAS评分非0 mm定义的带状疱疹后神经痛预防效果。

要点

  • 度洛西汀组在抗病毒药和镇痛药基础上加用度洛西汀,对照组不用度洛西汀。
  • 主要结局为带状疱疹发病后12周VAS评分非0 mm定义的PHN预防效果。
  • 纳入标准包括年龄>50岁、皮疹出现72小时内、VAS平均疼痛评分≥40/100 mm。

核心结论

  • 该试验旨在评估度洛西汀预给药是否可预防带状疱疹后神经痛的发生。

研究设计与样本

  • 全国多中心、随机、开放标签、盲法终点试验,计划从中国18个初级中心招募750例患者。
  • 纳入年龄>50岁、诊断为无并发症带状疱疹、皮疹出现72小时内、VAS平均疼痛评分至少40/100 mm的患者。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 主要结局:带状疱疹发病后12周VAS评分非0 mm定义为带状疱疹后神经痛,评估预防效果。
  • 次要结局包括每周平均VAS评分、每周各镇痛药平均用量、每周疼痛特征、基于12项简短健康调查的生活质量、患者总体变化印象量表、匹兹堡睡眠质量指数评估的睡眠质量及研究期间不良事件。

临床怎么用

  • 该方案探索度洛西汀在带状疱疹急性期预给药以降低带状疱疹后神经痛发生率的预防策略。

局限性

  • 原文为研究方案,尚无结果数据;开放标签设计可能影响部分主观结局的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postherpetic neuralgia (PHN) is the most common complication attributed to herpes zoster, which involves the reactivation of residual varicella zoster virus. It has been reported previously that pre-emptive amitriptyline following acute herpes zoster has shown latent positive effects in the prevention of PHN. In this study, by interfering with the same targets, norepinephrine and serotonin, we aim to evaluate whether pre-emptive duloxetine may proactively prevent PHN development. METHODS: This is a nationwide multicentric, randomized, open-label, blinded-endpoint study that will recruit 750 participants from 18 primary centres in China. Patients aged more than 50 years who are diagnosed with uncomplicated HZ, present with vesicles within 72 h of their emergence, and have an average pain score of at least 40/100 mm on a visual analogue scale (VAS, 0 mm = no pain, 100 mm = worst possible pain, at opposite ends of a 100-mm line) will be recruited for this study. Participants will be randomized into a duloxetine arm and a control arm. Participants allocated to the duloxetine arm will be given antivirals, analgesics and duloxetine, while those allocated to the control arm will receive antivirals and analgesics but no duloxetine. The primary outcome of this study is preventive efficacy against PHN, which will be evaluated based on a 100 mm VAS. Any pain scores other than 0 mm on the VAS 12 weeks after HZ onset will be defined as PHN. The secondary outcomes will consist of the average weekly VAS score, the average weekly consumption of each analgesic, weekly feature of the pain, patients' quality of life based on the 12-item Short-Form Health Survey, Patient Global Impression of Change Scale, sleep quality as evaluated by the Pittsburgh Sleep Quality Index and adverse events during the study period. DISCUSSION: This study will investigate a prophylactic approach for reducing the prevalence of postherpetic neuralgia with duloxetine and will add significant new knowledge on the preventive effects of duloxetine on PHN. TRIAL REGISTRATION: Clinicaltrials.gov NCT04313335 . Registered on 18 March 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen Z, Shrestha N, Zhao C, et al. Effect of duloxetine premedication for postherpetic neuralgia within 72 h of herpes zoster reactivation [PROCESS]: a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33298154. doi:10.1186/s13063-020-04919-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。